Literature DB >> 28360223

Risk stratification based on screening history: the NELSON lung cancer screening study.

Uraujh Yousaf-Khan1, Carlijn van der Aalst1, Pim A de Jong2, Marjolein Heuvelmans3, Ernst Scholten2,4, Joan Walter3, Kristiaan Nackaerts5, Harry Groen6, Rozemarijn Vliegenthart3, Kevin Ten Haaf1, Matthijs Oudkerk3, Harry de Koning1.   

Abstract

BACKGROUND: Debate about the optimal lung cancer screening strategy is ongoing. In this study, previous screening history of the Dutch-Belgian Lung Cancer Screening trial (NELSON) is investigated on if it predicts the screening outcome (test result and lung cancer risk) of the final screening round.
METHODS: 15 792 participants were randomised (1:1) of which 7900 randomised into a screening group. CT screening took place at baseline, and after 1, 2 and 2.5 years. Initially, three screening outcomes were possible: negative, indeterminate or positive scan result. Probability for screening outcome in the fourth round was calculated for subgroups of participants.
RESULTS: Based on results of the first three rounds, three subgroups were identified: (1) those with exclusively negative results (n=3856; 73.0%); (2) those with ≥1 indeterminate result, but never a positive result (n=1342; 25.5%); and (3) with ≥1 positive result (n=81; 1.5%). Group 1 had the highest probability for having a negative scan result in round 4 (97.2% vs 94.8% and 90.1%, respectively, p<0.001), and the lowest risk for detecting lung cancer in round 4 (0.6% vs 1.6%, p=0.001). 'Smoked pack-years' and 'screening history' significantly predicted the fourth round test result. The third round results implied that the risk for detecting lung cancer (after an interval of 2.5 years) was 0.6% for those with negative results compared with 3.7% of those with indeterminate results.
CONCLUSIONS: Previous CT lung cancer screening results provides an opportunity for further risk stratifications of those who undergo lung cancer screening. TRIAL REGISTRATION NUMBER: Results, ISRCTN63545820. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  Clinical Epidemiology; Lung Cancer; Smoking cessation; Tobacco and the lung

Mesh:

Year:  2017        PMID: 28360223     DOI: 10.1136/thoraxjnl-2016-209892

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  24 in total

Review 1.  Lung cancer screening-low dose CT for lung cancer screening: recent trial results and next steps.

Authors:  Emma Louise O'Dowd; David R Baldwin
Journal:  Br J Radiol       Date:  2017-10-17       Impact factor: 3.039

Review 2.  The narrow path to organized LDCT lung cancer screening programs in Europe.

Authors:  Eugenio Paci
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

3.  Lung cancer screening: tell me more about post-test risk.

Authors:  Mario Silva; Gianluca Milanese; Ugo Pastorino; Nicola Sverzellati
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

Review 4.  Appropriate screening intervals in low-dose CT lung cancer screening.

Authors:  Marjolein A Heuvelmans; Matthijs Oudkerk
Journal:  Transl Lung Cancer Res       Date:  2018-06

5.  Ten-year results of the Multicentric Italian Lung Detection trial demonstrate the safety and efficacy of biennial lung cancer screening.

Authors:  U Pastorino; N Sverzellati; S Sestini; M Silva; F Sabia; M Boeri; A Cantarutti; G Sozzi; G Corrao; A Marchianò
Journal:  Eur J Cancer       Date:  2019-07-20       Impact factor: 9.162

Review 6.  Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality.

Authors:  Asha Bonney; Reem Malouf; Corynne Marchal; David Manners; Kwun M Fong; Henry M Marshall; Louis B Irving; Renée Manser
Journal:  Cochrane Database Syst Rev       Date:  2022-08-03

Review 7.  Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Douglas E Wood; Ella A Kazerooni; Scott L Baum; George A Eapen; David S Ettinger; Lifang Hou; David M Jackman; Donald Klippenstein; Rohit Kumar; Rudy P Lackner; Lorriana E Leard; Inga T Lennes; Ann N C Leung; Samir S Makani; Pierre P Massion; Peter Mazzone; Robert E Merritt; Bryan F Meyers; David E Midthun; Sudhakar Pipavath; Christie Pratt; Chakravarthy Reddy; Mary E Reid; Arnold J Rotter; Peter B Sachs; Matthew B Schabath; Mark L Schiebler; Betty C Tong; William D Travis; Benjamin Wei; Stephen C Yang; Kristina M Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2018-04       Impact factor: 11.908

Review 8.  The role of gender in non-small cell lung cancer: a narrative review.

Authors:  Ioana Baiu; Ashley L Titan; Linda W Martin; Andrea Wolf; Leah Backhus
Journal:  J Thorac Dis       Date:  2021-06       Impact factor: 2.895

9.  Executive Summary: Screening for Lung Cancer: Chest Guideline and Expert Panel Report.

Authors:  Peter J Mazzone; Gerard A Silvestri; Lesley H Souter; Tanner J Caverly; Jeffrey P Kanne; Hormuzd A Katki; Renda Soylemez Wiener; Frank C Detterbeck
Journal:  Chest       Date:  2021-07-13       Impact factor: 9.410

10.  Screening for Lung Cancer: CHEST Guideline and Expert Panel Report.

Authors:  Peter J Mazzone; Gerard A Silvestri; Lesley H Souter; Tanner J Caverly; Jeffrey P Kanne; Hormuzd A Katki; Renda Soylemez Wiener; Frank C Detterbeck
Journal:  Chest       Date:  2021-07-13       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.